S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.16 (+3.32%)
MSFT   259.80 (+2.87%)
FB   194.18 (+0.33%)
GOOGL   2,220.58 (+1.95%)
AMZN   2,110.00 (-1.94%)
TSLA   666.17 (+0.34%)
NVDA   166.50 (-0.26%)
BABA   86.59 (-0.23%)
NIO   15.67 (-4.68%)
AMD   93.46 (-0.04%)
CGC   5.22 (-5.43%)
MU   69.18 (+0.41%)
T   20.82 (+2.06%)
GE   75.78 (+0.70%)
F   12.80 (+2.40%)
DIS   104.72 (+2.25%)
AMC   11.64 (-3.24%)
PFE   53.03 (+1.07%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.16 (+3.32%)
MSFT   259.80 (+2.87%)
FB   194.18 (+0.33%)
GOOGL   2,220.58 (+1.95%)
AMZN   2,110.00 (-1.94%)
TSLA   666.17 (+0.34%)
NVDA   166.50 (-0.26%)
BABA   86.59 (-0.23%)
NIO   15.67 (-4.68%)
AMD   93.46 (-0.04%)
CGC   5.22 (-5.43%)
MU   69.18 (+0.41%)
T   20.82 (+2.06%)
GE   75.78 (+0.70%)
F   12.80 (+2.40%)
DIS   104.72 (+2.25%)
AMC   11.64 (-3.24%)
PFE   53.03 (+1.07%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.16 (+3.32%)
MSFT   259.80 (+2.87%)
FB   194.18 (+0.33%)
GOOGL   2,220.58 (+1.95%)
AMZN   2,110.00 (-1.94%)
TSLA   666.17 (+0.34%)
NVDA   166.50 (-0.26%)
BABA   86.59 (-0.23%)
NIO   15.67 (-4.68%)
AMD   93.46 (-0.04%)
CGC   5.22 (-5.43%)
MU   69.18 (+0.41%)
T   20.82 (+2.06%)
GE   75.78 (+0.70%)
F   12.80 (+2.40%)
DIS   104.72 (+2.25%)
AMC   11.64 (-3.24%)
PFE   53.03 (+1.07%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.16 (+3.32%)
MSFT   259.80 (+2.87%)
FB   194.18 (+0.33%)
GOOGL   2,220.58 (+1.95%)
AMZN   2,110.00 (-1.94%)
TSLA   666.17 (+0.34%)
NVDA   166.50 (-0.26%)
BABA   86.59 (-0.23%)
NIO   15.67 (-4.68%)
AMD   93.46 (-0.04%)
CGC   5.22 (-5.43%)
MU   69.18 (+0.41%)
T   20.82 (+2.06%)
GE   75.78 (+0.70%)
F   12.80 (+2.40%)
DIS   104.72 (+2.25%)
AMC   11.64 (-3.24%)
PFE   53.03 (+1.07%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
NASDAQ:OSMT

Osmotica Pharmaceuticals (OSMT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.98
$1.49
52-Week Range
N/A
Volume
296,500 shs
Average Volume
396,682 shs
Market Capitalization
$69.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.34

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Osmotica Pharmaceuticals logo

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OSMT
Fax
N/A
Employees
302
Year Founded
N/A

Sales & Book Value

Annual Sales
$177.88 million
Book Value
$1.50 per share

Profitability

Net Income
$-79.59 million
Net Margins
-138.76%
Pretax Margin
-167.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
59,318,000
Market Cap
$69.47 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
5/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

846th out of 1,416 stocks

Pharmaceutical Preparations Industry

419th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

Is Osmotica Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Osmotica Pharmaceuticals stock.
View analyst ratings for Osmotica Pharmaceuticals
or view top-rated stocks.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) announced its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative trailing twelve-month return on equity of 81.23% and a negative net margin of 138.76%. During the same period in the previous year, the business earned ($0.14) EPS.
View Osmotica Pharmaceuticals' earnings history
.

What price target have analysts set for OSMT?

4 brokers have issued 12-month target prices for Osmotica Pharmaceuticals' stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Osmotica Pharmaceuticals' stock price to reach $5.33 in the next year.
View analysts' price targets for Osmotica Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Osmotica Pharmaceuticals' key executives?
Osmotica Pharmaceuticals' management team includes the following people:
  • Brian A. Markison, Chairman & Chief Executive Officer
  • James Schaub, Chief Operating Officer & Executive Vice President
  • Andrew J. Einhorn, Chief Financial Officer
  • Tina Devries, Executive VP-Research & Development
  • Sergio Alegre, Vice President-Global Compliance
What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), (CGC), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and AstraZeneca (AZN).

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

Who are Osmotica Pharmaceuticals' major shareholders?

Osmotica Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include HAP Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Osmotica Pharmaceuticals
.

Which institutional investors are buying Osmotica Pharmaceuticals stock?

OSMT stock was acquired by a variety of institutional investors in the last quarter, including HAP Trading LLC.
View insider buying and selling activity for Osmotica Pharmaceuticals
or or view top insider-buying stocks.

How much money does Osmotica Pharmaceuticals make?

Osmotica Pharmaceuticals has a market capitalization of $0.00 and generates $177.88 million in revenue each year. The company earns $-79.59 million in net income (profit) each year or ($1.590010) on an earnings per share basis.

How many employees does Osmotica Pharmaceuticals have?

Osmotica Pharmaceuticals employs 302 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at (908) 809-1300 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.